一期法FVIII活性反映AAV来源FVIII增强的凝血酶激活并预测表型
本研究在基因治疗小鼠和SPK-8011试验参与者中比较AAV来源FVIII-SQ与重组FVIII-SQ的激活与功能。结果显示AAV-FVIII-SQ辅因子功能正常且A2域稳定,其增强的凝血酶介导激活可被一期法(OSA)而非发色底物法(CSA)检测。对23例SPK-8011参与者的分析提示OSA较CSA对年化出血率预测趋势更好,OSA活性与止血功能更相关。
要点
- AAV-FVIII-SQ的OSA活性高于CSA 1.5-2倍,源于增强的凝血酶激活。
- OSA活性与小鼠止血功能及rFVIII-SQ功能更一致。
- OSA较CSA对SPK-8011参与者年化出血率预测趋势更好。
核心结论
- OSA FVIII活性反映AAV-FVIII-SQ在内源性Tenase复合物中的功能,捕捉CSA未检测的增强激活,并最好地预测临床结局。
研究设计与样本
- 在基因治疗小鼠和SPK-8011试验参与者中比较AAV-FVIII-SQ与rFVIII-SQ的激活和功能。
- 对23例SPK-8011参与者(累积99患者年)进行负二项回归分析。
主要发现
- 在两种物种中,AAV-FVIII-SQ显示正常辅因子功能和A2域稳定性。
- 在小鼠中,无VWF时检测差异持续存在,表明不由VWF相互作用改变驱动。
- 两种物种中AAV-FVIII-SQ的凝血酶介导激活增强,可被OSA而非CSA检测。
- 负二项回归分析显示OSA较CSA对年化出血率预测趋势更好。
- 小鼠体内评估显示OSA活性与止血功能更相关,并与rFVIII-SQ功能一致。
关键数值与推荐
- OSA FVIII活性超过CSA值1.5倍至2倍。
- 23例SPK-8011参与者代表99累积患者年。
临床怎么用
- 在AAV-FVIII-SQ基因治疗中,OSA可能更准确反映止血功能和预测出血表型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hemophilia A (HA) phenotype is predicted by factor VIII (FVIII) activity. Most HA adeno-associated virus (AAV) trials incorporate the B-domain-deleted FVIII-SQ variant, and 1-stage assay (OSA) FVIII activity exceeds chromogenic substrate assay (CSA) values by 1.5-fold to twofold. This contrasts with recombinant FVIII-SQ (rFVIII-SQ), suggests altered biochemical properties, and highlights the need to determine which assay reflects hemostatic function. In gene therapy-treated mice and SPK-8011 trial participants, AAV-derived FVIII-SQ (AAV-FVIII-SQ) activation and function within the intrinsic tenase enzyme complex was compared with rFVIII-SQ. In both species, AAV-FVIII-SQ demonstrated normal cofactor function and A2-domain stability. In mice, the assay discrepancy persisted without von Willebrand factor (VWF), indicating it is not driven by altered VWF interactions. Both species demonstrated enhanced thrombin-mediated activation of AAV-FVIII-SQ, detectable by OSA but not CSA. Negative binomial regression analysis of 23 SPK-8011 participants, representing 99 cumulative patient-years, trended toward better prediction of annualized bleeding rate with OSA than CSA. In vivo evaluation of AAV-FVIII-SQ in mice demonstrated that OSA activity better correlated with hemostatic function and corresponded to rFVIII-SQ function. These findings support that OSA FVIII activity reflects AAV-FVIII-SQ function within the intrinsic tenase complex, captures enhanced activation not detected by CSA, and best predicts clinical outcome.
引用
- Sternberg AR, Watson CT, Davidson RJ, et al. One-stage assay factor VIII activity reflects AAV-derived factor VIII-enhanced thrombin activation and predicts phenotype. Blood. 2026. PMID: 42371804. doi:10.1182/blood.2025032890
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。